An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Inclusion Criteria: * Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa * At least four weeks following prior standard treatment, with no evidence of disease * Must use adequate birth control Exclusion Criteria: * Prior cancer vaccine therapy or concurrent participation in any other investigational study * A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment * A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine * Women who are pregnant, intend to become pregnant, or who are breast feeding